



MALCOLM WILLET

- ANALYSIS, p 23
- FEATURE, p 28

NEWS

- 1 Treatment for ADHD reduces criminal behaviour
Doctors must put needs of child before relationship with parents, judge rules
- 2 GP is held responsible for brain damage of child who was discharged from hospital after head injury
Belief not science is behind flu jab promotion
- 3 Mammography again linked to cancer overdiagnosis
- 4 Fasting makes little difference to results of routine lipid level tests
Investigations begin into death of woman who was refused an abortion
- 5 Missing notes mean case against doctor arrested in UAE is deferred
UK could get first meningitis B vaccine next year
- 6 Smokers respond more to pictures than words
Recession leads to first fall in health spending in Europe since 1975, says OECD report
Family of patient who died during a trial receives a six figure settlement



Treating ADHD with drugs reduces criminal behaviour, p 1

RESEARCH

RESEARCH HIGHLIGHTS

- 11 The pick of *BMJ* research papers this week

RESEARCH NEWS

- 12 All you need to read in the other general journals

RESEARCH PAPERS

- 14 General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis
Lasse T Krogsbøll et al
● EDITORIAL, p 7
- 15 Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial
On behalf of the VIPER-BP study investigators
● EDITORIAL, p 8
- 16 Muscular strength in male adolescents and premature death: cohort study of one million participants
Francisco B Ortega et al
- 17 Sharing of clinical trial data among trialists: a cross sectional survey
Vinay Rathi et al
● EDITORIAL, p 10
- 18 Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials
Benjamin D Fox et al
- 19 When is a further clinical trial justified?
Manuela L Ferreira et al

RESEARCH METHODS AND REPORTING

COMMENT

EDITORIALS



Evidence is scant that periodic health checks cut illness, p 7

- 7 The value of conducting periodic health checks
Domhnall MacAuley
● RESEARCH, p 14
- 8 The use of highly structured care to achieve blood pressure targets
Christopher E Clark and Richard McManus
● RESEARCH, p 15
- 9 Call for worldwide withdrawal of tiotropium Respimat mist inhaler
Richard Beasley et al
- 10 The new *BMJ* policy on sharing data from drug and device trials
Fiona Godlee and Trish Groves

ANALYSIS

- 23 How to achieve international action on falsified and substandard medicines
Substandard and falsified medicines kill patients, yet progress on the twin challenges of safeguarding the quality of genuine medicine and criminalising falsified ones has been held back by controversy over intellectual property rights and confusion over terms. Amir Attaran and colleagues propose a global treaty to overcome the problems
- 27 Commentary: Substandard medicines are the priority for neglected tropical diseases
Thomas P C Dorlo et al

FEATURES

- 28 Faking it
Globalisation has helped increase the risks of counterfeit drugs endangering human life. Andrew Jack looks at the scale of the problem and the latest attempts to crack down on crime



Dealing with the problem of counterfeit drugs, p 28

Articles appearing in this print journal have already been published on bmj.com, and the version in print may have been shortened. bmj.com also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on bmj.com.

Please cite all articles by year, volume, and elocator (rather than page number), eg *BMJ* 2012; 344:d286.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.



Obituary of the “father of bone marrow transplantation,” p 38

COMMENT

LETTERS

- 30 Breast screening review; Safety of antithrombosis stockings; Prison environment and health
- 31 Awareness about antibiotics; Diagnosis of tuberculosis; Salivary gland swellings
- 32 Myalgia while taking statins; Imprisonment of Cyril Karabus; Bad medicine: medical nutrition
- 33 Future of WHO; Whistleblowing barriers in the NHS; Forty years of murder

OBSERVATIONS

LIFE AND DEATH

- 34 Falling through the gaps in care Iona Heath

ETHICS MAN

- 35 How good a doctor do you need to be? Daniel K Sokol

VIEWS AND REVIEWS

PERSONAL VIEW

- 36 Junior doctors take heart Anthony Cohn



An encouraging message to junior doctors, p 36

BETWEEN THE LINES

- 37 The tale of a mad hatter Theodore Dalrymple

MEDICAL CLASSICS

- 37 The Ha Ha A novel by Jennifer Dawson
Kate Robertson

OBITUARIES

- 38 Edward Donnall Thomas
Nobel laureate, known as the father of bone marrow transplantation
- 39 Peter William Hayward; Colin Kaplan; Cyril Jacob Kaplan; Alan Colin Markland; Elwyn Roberts; Jose A Socrates; Thomas Glyn Thomas

LAST WORDS

- 51 The peeved middle Des Spence
A short history of pharmaceutical marketing
Robin Ferner

EDUCATION

CLINICAL REVIEW

- 40 Resistant hypertension
Aung Myat et al

PRACTICE

CHANGE PAGE

- 46 Administer tranexamic acid early to injured patients at risk of substantial bleeding
Russell L Gruen and Michael C Reade

A PATIENT'S JOURNEY

- 48 Neuromuscular degeneration
Caroline Fisher and Nicole Freris

ENDGAMES

- 50 Quiz page for doctors in training

MINERVA

- 52 Quails' eggs, and other stories



Loss of vision in Minerva, p 52

Too much information and not enough time?

BMJ Masterclasses

masterclasses.bmj.com



The Editor, *BMJ*
 BMA House, Tavistock Square,
 London WC1H 9JR
 Email: editor@bmj.com
 Tel: +44 (0)20 7387 4410
 Fax: +44 (0)20 7383 6418
BMA MEMBERS' INQUIRIES
 Email: membership@bma.org.uk
 Tel: +44 (0)20 7383 6642
BMJ CAREERS ADVERTISING
 Email: sales@bmjcareers.com
 Tel: +44 (0)20 7383 6531
DISPLAY ADVERTISING
 Email: sales@bmjgroup.com
 Tel: +44 (0)20 7383 6386
REPRINTS
 UK/Rest of world
 Email: ngurneyrandall@bmjgroup.com
 Tel: +44 (0)20 8445 5825
 USA
 Email: mfogler@medicalreprints.com
 Tel: +1 (856) 489 4446
SUBSCRIPTIONS
 BMA Members
 Email: membership@bma.org.uk
 Tel: +44 (0)20 7383 6642
 Non-BMA Members
 Email: support@bmjgroup.com
 Tel: +44 (0)20 7383 6270
OTHER RESOURCES
 For all other contacts:
 resources.bmj.com/bmj/contact-us
 For advice to authors:
 resources.bmj.com/bmj/authors
 To submit an article:
 submit.bmj.com

The BMJ is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the *BMJ*. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The *BMJ* follows guidelines on editorial independence produced by the World Association of Medical Editors (www.wame.org/wamestmt.htm#independence) and the code on good publication practice produced by the Committee on Publication Ethics (www.publicationethics.org.uk/guidelines/).

The *BMJ* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the *BMJ* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2012
 All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the *BMJ*.

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to *BMJ*, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796.

Weekly
 Printed by Polestar Limited



MARK THOMAS

PICTURE OF THE WEEK

Doctors who have launched a new political party that promises to make the NHS one of the key issues at the next election gathered in London last week. They aim to oppose the government's changes to healthcare and to protect the NHS from the threat of austerity measures. The party hopes to put forward up to 50 parliamentary candidates in 2015 in carefully selected areas and in local elections.

bmj.com • *BMJ* 2012;345:e7731

RESPONSE OF THE WEEK

This article makes explicit the approach that many general practitioners feel they already aspire to, and being aware of our personal biases and cognitive processes during the consultation can only help us to become better doctors. Unfortunately, in the UK this approach is coming under increasing threat.

Despite the government's mantra 'no decision about me without me,' the reality is that with the increasing demands from performance management, GPs are under pressure to disregard patient preferences and to manage them according to strict and simplistic protocols. The proposed new GP contract threatens to intensify this. In one of the many internal tensions within the current NHS, the claim to honour the wishes of the patient is at odds with the desire to micromanage how we treat them. As the QOF juggernaut hurtles blindly onward, shared decision making will be one of the casualties.

Jonathan D Sleath, general practitioner, Hereford, UK, in response to "Stop the silent misdiagnosis: patients' preferences matter" (*BMJ* 2012;345:e6572)

BMJ.COM POLL

Last week's poll asked: "Is the Liverpool care pathway fit for purpose?"

73% voted yes (total 467 votes cast)

► Feature (*BMJ* 2012;345:e7644)

This week's poll asks: "In view of increasing antimicrobial resistance worldwide, have you changed your prescribing practice for antibiotics?"

► News (*BMJ* 2012;345:e7778)

► [Vote now on bmj.com](http://bmj.com)

MOST READ

Clinical trial data for all drugs in current use

Minerva

Psychotic depression

Plantar fasciitis

Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease



ALAMY

MOST COMMENTED ON

Psychotic depression

Clinical trial data for all drugs in current use

Promoting cosmetic surgery

Breast screening is beneficial, panel concludes, but women need to know about harms

A licence to bill

EDITOR'S CHOICE

Time for global action on fake medicines

The world currently has tighter laws to tackle fake tobacco products than it does to tackle fake drugs

► To receive Editor's Choice by email each week, visit www.bmj.com/newaccount

Twitter

► Follow the editor, Fiona Godlee, at twitter.com/fgodlee, and the *BMJ* at twitter.com/bmj_latest



Sign up today using your smartphone

—follow these steps:

- Download a free QR reader from your handset's app store
- Hold your smartphone over the QR code
- You will then be forwarded to the email sign up page

In an article this week a self defined “diverse group of authors from the health professions, health charities, legal and medical academia, and former or current government officials in health” present us with a troubling paradox: the world currently has tighter laws to tackle fake tobacco products than it does to tackle fake drugs (p 23). At the moment, as they explain, there are laws that promote an open global medicines trade but no binding international health law on drug safety. The result is that fake and substandard drugs continue to harm and kill people around the world, affecting both proprietary and generic drugs, and haunting rich countries as well as poor. As Andrew Jack explains (p 28), the rapid growth of unregulated internet sales of drugs has raised the stakes even further. In the accompanying podcast, Amir Attaran emphasises the absurd situation by which trading fake medicines is currently legal under international law, and Sania Nishtar highlights worryingly weak pharmacovigilance systems in Pakistan (www.bmj.com/multimedia).

Why the lack of progress on this globally damaging health problem? There's no simple answer to what is clearly a complex problem, but the authors suggest that the main barriers have been the lack of an internationally agreed terminology and a focus in law on commercial interests rather than public health.

Progress has also been hampered by a lack of good data on the scale of the problem. WHO estimates that over 10% of drugs in developing countries may be “counterfeit,” but getting a better idea of the impact is proving difficult. The drug industry keeps records of “medicine crimes,” but these are held in secret so are not available to researchers or governments wanting to raise awareness and improve patient safety. But recent incidents are focusing minds. Contaminated methylprednisolone has killed 28 people from meningitis in the United States this year

(*BMJ* 2012;345:e7095) and more than 125 people were killed in Pakistan by generic isosorbide-5-mononitrate tablets adulterated with a toxic dose of antimalarial (*BMJ* 2012;344:e951). These incidents are the visible tip of a vast iceberg of failed treatment, adverse reaction, and death.

With less than a third of WHO member states having well developed drug regulation, reliance on national governments to resolve things is unlikely to work. In a linked commentary, Thomas Dorlo and colleagues call for more resources to support national regulators (p 27).

The *BMJ* “diverse group of authors” has come together to call for global action. They propose a treaty modelled on the successful Framework Convention on Tobacco Control and, to help get us there, a simpler terminology. In place of WHO's current all encompassing working definition “SFFC”—which stands for spurious, falsely labelled, falsified, counterfeit medical products, and which in some versions has an additional “S” for substandard—they propose a clearer focus on falsified and substandard drugs.

Both categories cause harm but they require different remedies. “Falsified medicines are deliberate, intentional frauds and should be prohibited using criminal measures. In contrast, substandard medicines are unintentional or negligent errors that require regulatory measures to correct.” The US methylprednisolone incident looks likely to have been caused by poor standards rather than criminal intent. In Pakistan, if allegations are confirmed that the company knew of the error and sold the drug anyway, the incident may be reclassified as falsified.

This week, WHO member states met in Buenos Aires to try to take things forward. They could do worse than to follow these authors' advice.

Fiona Godlee, editor, *BMJ* fgodlee@bmj.com

Cite this as: *BMJ* 2012;345:e7917

All you need is ... bmj.com

Whether you are a medical professional, academic researcher, or are working in health policy or public health, bmj.com offers something valuable for you. Browse regular blogs, podcasts, videos, research, education, and the latest medical news.

Browse
bmj.com



BMJ